Wegovy vs Retatrutide in Special Populations: A Head-to-Head Clinical Comparison

What Are Wegovy and Retatrutide, and How Do They Differ Mechanistically?

Wegovy delivers semaglutide at 2.4 mg weekly via subcutaneous injection, activating GLP-1 receptors to suppress appetite, slow gastric emptying, and modestly increase insulin secretion. Retatrutide adds co-agonism at GIP and glucagon receptors on top of GLP-1 activity, producing a broader metabolic signal that may explain its substantially larger weight-loss numbers in early trials.

GLP-1 Receptor Agonism: Shared Ground

Both drugs activate GLP-1 receptors, driving similar downstream effects: reduced caloric intake, slower gastric emptying, and improved glycemic control. The GLP-1 pathway is the best-characterized mechanism in this drug class, with semaglutide's effects documented in STEP-1 (N=1,961), where participants receiving semaglutide 2.4 mg lost a mean of 14.9% of body weight over 68 weeks versus 2.4% with placebo (Wilding et al., NEJM 2021).

The Triple Agonist Difference

Retatrutide's additional GIP receptor agonism may amplify insulin secretion and fat oxidation beyond what GLP-1 alone provides. Its glucagon receptor co-agonism increases hepatic glucose output and thermogenesis. In the Jastreboff et al. Phase 2 trial (N=338), participants receiving retatrutide 12 mg weekly achieved a mean weight reduction of 24.2% at 48 weeks, compared with 2.1% for placebo (Jastreboff et al., NEJM 2023). That magnitude of loss is approximately 62% greater than what STEP-1 recorded for semaglutide at a similar timepoint.

Receptor Profile Implications for Special Populations

The glucagon receptor component of retatrutide raises specific considerations in people with type 2 diabetes, where glucagon dysregulation already contributes to hyperglycemia. Clinicians will need to monitor fasting glucose more frequently during retatrutide titration in this group. The GIP co-agonism, by contrast, may offer cardiovascular and renal benefits that are still being characterized in ongoing Phase 3 work.

Wegovy in Special Populations: What the Trials Show

Semaglutide 2.4 mg has the most complete special-population dataset of any approved obesity drug, drawn from the full STEP program across eight trials enrolling more than 4,500 participants.

Type 2 Diabetes (STEP-2)

STEP-2 enrolled 1,210 adults with obesity and type 2 diabetes. Participants receiving semaglutide 2.4 mg lost a mean of 9.6% of body weight at 68 weeks versus 3.4% with placebo, and HbA1c fell by 1.6 percentage points in the semaglutide group (Davies et al., Lancet 2021). Weight loss was lower than in the non-diabetic STEP-1 cohort, a pattern consistent across GLP-1 drugs and attributed partly to baseline insulin use and beta-cell dysfunction. Clinicians should expect modestly attenuated weight loss in patients with T2D on Wegovy and counsel accordingly.

Cardiovascular Disease (SELECT Trial)

The SELECT cardiovascular outcomes trial enrolled 17,604 adults with pre-existing cardiovascular disease and a BMI of 27 or higher but without diabetes. Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% versus placebo over a median follow-up of 34.2 months (Lincoff et al., NEJM 2023). This is the first demonstrated cardiovascular mortality benefit for any obesity pharmacotherapy, and it substantially shapes prescribing decisions for patients with atherosclerotic cardiovascular disease. No comparable outcomes trial exists for retatrutide.

Chronic Kidney Disease

Post-hoc analyses of STEP-2 data and separate renal subgroup analyses indicate that semaglutide 2.4 mg may slow eGFR decline in patients with obesity-related CKD. The FLOW trial of semaglutide 1.0 mg (Ozempic dose) in T2D with CKD showed a 24% reduction in the composite kidney endpoint (Perkovic et al., NEJM 2024). While FLOW used a lower dose than Wegovy, the mechanism is shared, and the data support cautious optimism for renal benefit at the 2.4 mg dose. Retatrutide's renal profile in CKD remains uncharacterized outside small Phase 2 subgroups.

Obesity Class III (BMI ≥40)

In STEP-1, participants with a baseline BMI of 40 or higher achieved numerically larger absolute weight reductions than lower-BMI subgroups, though percentage weight loss was similar across BMI strata. Retatrutide's Phase 2 trial enrolled participants with a mean BMI of approximately 37.3 kg/m2, so its performance in class III obesity specifically is not yet established (Jastreboff et al., NEJM 2023).

Retatrutide in Special Populations: Phase 2 Data and Projections

Retatrutide's special-population data are limited to the Phase 2 trial and early Phase 3 disclosures. Drawing firm conclusions is premature. What the available data do show, however, is a dose-dependent weight-loss curve steeper than any approved GLP-1 agent.

Phase 2 Dose-Response Across Subgroups

The Jastreboff et al. Phase 2 trial tested retatrutide at 1 mg, 4 mg, 8 mg, and 12 mg weekly in adults with obesity (BMI 30 to 50) without diabetes. At 48 weeks, the 4 mg group lost 17.3%, the 8 mg group lost 22.8%, and the 12 mg group lost 24.2% of body weight (Jastreboff et al., NEJM 2023). Even the lowest active dose outperformed the placebo-adjusted loss seen in STEP-1 for semaglutide. The trial excluded patients with T2D, CKD stages 4 to 5, and recent cardiovascular events, which limits direct applicability to those groups.

Type 2 Diabetes Subgroup

A parallel Phase 2 trial examined retatrutide in adults with T2D and obesity. Early data presented at scientific meetings suggested HbA1c reductions of approximately 2.0 to 2.2 percentage points at 24 weeks in the higher-dose arms, comparable to tirzepatide's T2D performance in SURPASS-1 (Frias et al., Lancet 2021). The glucagon co-agonism creates a theoretical risk of attenuated glycemic control in some T2D phenotypes, which Phase 3 data will need to clarify.

Cardiovascular and Renal Projections

No cardiovascular outcomes trial for retatrutide has reported results. The magnitude of weight loss alone may confer cardiovascular benefit by reducing adiposity-driven inflammation, but the SELECT trial established that semaglutide's MACE reduction was only partly explained by weight loss, pointing to pleiotropic drug effects (Lincoff et al., NEJM 2023). Whether retatrutide's glucagon component helps or hinders long-term cardiovascular outcomes remains an open question. For patients with established CVD, Wegovy's 34-month outcomes dataset makes it the more defensible choice today.

Head-to-Head Comparison by Special Population

No randomized trial has directly compared Wegovy and retatrutide in any population. The following synthesis draws from trial-level data, applying consistent endpoints where available.

Adults Without Diabetes and Obesity Class I to III

This is retatrutide's strongest domain based on current data. The Phase 2 trial's 24.2% weight loss at 48 weeks exceeds STEP-1's 14.9% at 68 weeks, even accounting for the shorter duration (Jastreboff et al., NEJM 2023); (Wilding et al., NEJM 2021). If Phase 3 trials confirm this signal, retatrutide may become the preferred agent for patients with obesity and no major comorbidities who are primarily seeking maximum weight reduction.

Adults With Type 2 Diabetes

Wegovy currently holds the advantage here, with 68-week T2D-specific data from STEP-2 and a well-characterized safety profile in this group. Retatrutide's glucagon co-agonism requires careful glucose monitoring in T2D and has not yet been validated in a large, long-duration T2D cohort. Clinicians managing patients with T2D should not switch to retatrutide outside a clinical trial setting until Phase 3 T2D outcomes are published.

Adults With Established Cardiovascular Disease

SELECT is definitive for semaglutide 2.4 mg: a 20% reduction in MACE in a 17,604-person trial over 34 months, with an absolute risk reduction of 1.5 percentage points (Lincoff et al., NEJM 2023). Retatrutide has no published cardiovascular outcomes data. For any patient with prior MI, stroke, or symptomatic peripheral arterial disease, Wegovy is the only evidence-supported choice in this drug class at the 2.4 mg dose.

Chronic Kidney Disease Stages 2 to 4

Semaglutide's renal benefit data from FLOW, combined with its established metabolic effects, support its use in CKD stages 2 to 3 with appropriate dose monitoring (Perkovic et al., NEJM 2024). Retatrutide is not yet studied in CKD stage 3b or higher. The glucagon receptor agonism theoretically could affect renal hemodynamics, though this is speculative without dedicated nephrology-endpoint trial data.

Post-Bariatric Patients

Neither drug has a dedicated trial in post-bariatric populations. Semaglutide 1.0 mg data in post-sleeve patients show modest additional weight loss, and the 2.4 mg dose is increasingly used off-label in this group. Retatrutide's higher efficacy ceiling could be especially useful for patients with significant weight recurrence after bariatric surgery, but no published data support this application yet.

HealthRX Population-Selection Framework

The table below summarizes the current evidence-based preference by population. This framework will be updated as Phase 3 retatrutide data are published.

| Population | Preferred Agent (2025) | Rationale | |---|---|---| | Obesity, no T2D, no CVD | Retatrutide (when approved) | Larger Phase 2 weight loss; no contraindications | | Obesity + T2D | Wegovy (semaglutide 2.4 mg) | STEP-2 68-week T2D data; validated HbA1c reduction | | Obesity + established CVD | Wegovy (semaglutide 2.4 mg) | SELECT: 20% MACE reduction, N=17,604 | | Obesity + CKD stage 2-3 | Wegovy (semaglutide 2.4 mg) | FLOW renal-endpoint data; established safety | | Post-bariatric weight recurrence | Wegovy (off-label); monitor closely | No retatrutide data; semaglutide real-world use growing | | Obesity class III, no comorbidities | Retatrutide (when approved) | 24.2% loss at 48 weeks in Phase 2 |

Tolerability and Side-Effect Profiles Across Populations

Both drugs share GLP-1-class gastrointestinal side effects: nausea, vomiting, diarrhea, and constipation. These are typically dose-dependent and transient.

Semaglutide 2.4 mg Tolerability

In STEP-1, nausea occurred in 44.2% of semaglutide participants versus 16.0% with placebo, leading to discontinuation in 4.5% of the active group (Wilding et al., NEJM 2021). Serious adverse events were numerically lower in the semaglutide group overall, though gallbladder events (cholelithiasis, cholecystitis) occurred in 2.6% versus 1.2% with placebo. Patients with a history of pancreatitis or medullary thyroid carcinoma are contraindicated.

Retatrutide Tolerability

In Jastreboff et al. Phase 2, GI side effects were dose-dependent. At 12 mg, nausea occurred in 42% of participants, vomiting in 28%, and diarrhea in 26% (Jastreboff et al., NEJM 2023). Discontinuation due to adverse events was 16% in the 12 mg group, higher than the semaglutide discontinuation rate in STEP-1. Heart rate increases of approximately 5 to 8 beats per minute were observed across retatrutide doses, a finding consistent with GLP-1 and glucagon class effects that requires monitoring in patients with arrhythmia or tachycardia.

Special Population Tolerability Considerations

Patients with CKD may tolerate lower doses more readily due to altered drug clearance kinetics, though semaglutide's renal clearance is minimal given its high albumin binding. Older adults (age 65 and older) were underrepresented in the retatrutide Phase 2 trial, limiting tolerability data for this group. Wegovy's STEP-5 trial (104 weeks, N=304) provides longer-term tolerability data, showing sustained GI side-effect profiles without new safety signals (Garvey et al., Nature Medicine 2022).

Switching from Wegovy to Retatrutide: Clinical Considerations

Because retatrutide is not yet FDA-approved, switching from Wegovy to retatrutide currently occurs only within clinical trials or on an individual compassionate-use basis. The following guidance applies to anticipated real-world use after approval.

Pharmacological Overlap at Switch

Semaglutide has a half-life of approximately 7 days, meaning serum concentrations remain detectable for 4 to 5 weeks after the last dose. Initiating retatrutide while semaglutide is still pharmacologically active could amplify GI side effects during early titration. A 4-week gap between the last Wegovy dose and the first retatrutide dose may reduce this risk, though no pharmacokinetic bridging study has been published.

Managing Expectations During the Switch

Patients switching from Wegovy who have reached plateau weight loss may see an additional 8 to 14 percentage points of body weight reduction if retatrutide Phase 2 data translate to Phase 3 results. Clinicians should set realistic expectations: early weeks of retatrutide titration may involve more nausea than the patient experienced on a stable Wegovy dose, and weight loss may temporarily stall before the new drug reaches steady-state efficacy.

Monitoring Parameters After Switching

Patients with T2D who switch should have fasting glucose checked at 2 and 4 weeks after starting retatrutide, given the glucagon receptor agonism. Heart rate should be measured at each visit during the first 12 weeks. Renal function monitoring is reasonable in any patient with baseline CKD, though semaglutide's discontinuation itself may transiently affect GFR given GLP-1's renal hemodynamic effects (Perkovic et al., NEJM 2024).

The American Association of Clinical Endocrinology 2023 obesity guidelines state: "Selection of pharmacotherapy should be individualized based on comorbidities, contraindications, patient preference, and drug availability, with periodic reassessment of response and tolerability" (Garvey et al., Endocrine Practice 2022). This framing applies directly to any switch decision between Wegovy and retatrutide.

Regulatory Status and Access

Wegovy received FDA approval in June 2021 for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity (FDA, NDA 215256). Its indication was expanded in March 2024 to include cardiovascular risk reduction in adults with CVD and obesity, based on SELECT trial data.

Retatrutide (LY3437943) is being developed by Eli Lilly. As of early 2025, Phase 3 trials are ongoing. No NDA has been submitted. Anticipated approval, contingent on Phase 3 results, is projected by some analysts for 2026, though regulatory timelines are variable and this projection carries no guarantee.